Tags Archive Navigation
icon
-
Media Release
Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten
-
Media ReleaseNovartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
-
Media ReleaseSandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
-
Media ReleaseNovartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
-
Media ReleaseNovartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
-
Media ReleaseNovartis announces partnership with the American Society of Hematology to fight sickle cell disease in Sub-Saharan Africa
-
Media ReleaseSandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
-
Media ReleaseNovartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
-
Media ReleaseNovartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
-
Media ReleaseNovartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions
-
Media ReleaseNovartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond
-
Media ReleaseNovartis au T3: performance solide, croissance de 11% du résultat opérationnel core, chiffre d’affaires net proche de l’an dernier, pipeline en fort progrès; hausse du résultat opérationnel core prévu